BIOCRYST PHARMACEUTICALS INC (BCRX) Form 8-K — Aug 5, 2026
BioCryst Pharmaceuticals reported second quarter 2026 total revenue of $218.3 million, up 34% year over year, with ORLADEYO net revenue of $158.2 million. The company posted a $98.5 million GAAP operating profit, $113.2 million non-GAAP operating profit, and GAAP net income of $78.4 million, or $0.31 per basic share. Management raised full year 2026 total revenue guidance to $690-715 million from $635-660 million, maintained ORLADEYO guidance of $625-645 million, and lowered non-GAAP operating expense guidance to $420-440 million.
Key figures
- Eps
- 0.31 basic / 0.30 diluted
- Revenue
- 218250000
- Guidance
- FY2026 total revenue raised to $690-715 million (from $635-660 million); ORLADEYO revenue maintained at $625-645 million; non-GAAP operating expense lowered to $420-440 million (from $450-470 million)
- Net Income
- 78395000
- Revenue Yoy
- +34% y/y (+45% comparable ex-Europe)
- Total Assets
- 557851000
- Cash Position
- 354000000
- Shares Outstanding
- 255265000
- Secured Term Loan
- 395400000
- Interest Expense Q2
- 21712000
- Orladeyo Q2 Revenue
- 158202000
- Orladeyo Revenue Yoy
- +1% as reported; +10% comparable ex-Europe
- Gaap Operating Profit Q2
- 98465000
- Navenibart Royalty Rate
- 18%-30% tiered on net sales
- Acquired IPRDCharge Astria
- 697761000
- Navenibart License Upfront
- 70000000
- Non Gaap Operating Profit Q2
- 113157000
- License Revenue Recognized Q2
- 55700000
- Royalty Financing Obligation
- 426789000
- Navenibart Topline Data Timing
- Q3 2027
- Orladeyo Pellet Prescriptions YTD
- 47
- Navenibart License Potential Milestones
- 275000000
Price after filing
Close on the filing date to close N calendar days later (from $9.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.